Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: An observational cohort study

BMJ Open

Volumn 2, Issue 5, 2012, Pages

  Kastbom, Alf ^a   Cöster, Lars ^a   Ärlestig, Lisbeth ^b   Chatzidionysiou, Aikaterini ^c,d   Van Vollenhoven, Ronald F ^c,d   Padyukov, Leonid ^c   Rantapää Dahlqvist, Solbritt ^b   Saevarsdottir, Saedis ^c  

^a LINKÖPING UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FC GAMMA RECEPTOR IIIA; FC RECEPTOR; GLUCOCORTICOID; IMMUNOGLOBULIN BINDING FACTOR; IMMUNOGLOBULIN G; RHEUMATOID FACTOR; RITUXIMAB; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE COURSE; DISEASE DURATION; DISEASE PREDISPOSITION; DRUG EFFECT; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; TREATMENT RESPONSE;

EID: 84869854648     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-001524     Document Type: Article

References (18)

1. Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997;100:1059-70.
2. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8.
3. Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol 2005;23:474-81.
4. Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004;199:1659-69.
5. Dall'Ozzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004;64:4664-9.
6. Ruyssen-Witrand A, Rouanet S, Combe B, et al. Fcgamma receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 2012;71:875-7.
7. Kastbom A, Ahmadi A, Soderkvist P, et al. The 158V polymorphism of Fc gamma receptor type IIIA in early rheumatoid arthritis: increased susceptibility and severity in male patients (the Swedish TIRA project). Rheumatology (Oxford) 2005;44:1294-8.
8. Lee YH, Ji JD, Song GG. Associations between FCGR3A polymorphisms and susceptibility to rheumatoid arthritis: a metaanalysis. J Rheumatol 2008;35:2129-35.
9. Thabet MM, Huizinga TW, Marques RB, et al. Contribution of Fcgamma receptor IIIA gene 158V/F polymorphism and copy number variation to the risk of ACPA-positive rheumatoid arthritis. Ann Rheum Dis 2009;68:1775-80.
10. Robinson JI, Barrett JH, Taylor JC, et al. Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease. Ann Rheum Dis 2010;69:1054-7.
11. Kramer PR, Winger V, Kramer SF. 17beta-estradiol utilizes the estrogen receptor to regulate CD16 expression in monocytes. Mol Cell Endocrinol 2007;279:16-25.
12. van Gestel AM, Prevoo ML, van't Hof MA, et al. Development and validation of the European League against rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
13. Kastbom A, Bratt J, Ernestam S, et al. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:448-52.
14. Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003;48:455-9.
15. Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003;48:2146-54.
16. Rosengren S, Wei N, Kalunian KC, et al. Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab. Arthritis Res Ther 2008;10:R105.
17. Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease - the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007;3:86-95.
18. Niederer HA, Willcocks LC, Rayner TF, et al. Copy number, linkage disequilibrium and disease association in the FCGR locus. Hum Mol Genet 2010;19:3282-94.